Skip to content

Why Early Treatment Was Blocked for EUA Shots

Day 1 · 2:15:17 · Ron Johnson

  • 📜 FDA EUA rules require no adequate approved alternative, creating incentive to suppress cheap generics.
  • 💊 Johnson recounts Novartis HCQ enthusiasm then radio silence once CDC/Warp Speed locked onto mRNA.
  • 📚 Merriam-Webster’s vaccine definition was changed so rising antibodies alone counted as success.

EUA law and platform politics explain the war on early outpatient drugs.

← Q&A: Where Do Governments and the Vaccine-Injured Go From Here? | mRNA Shots as Gene Therapy That Does Not Degrade →

Transcript

Ron Johnson · 2:15:17

Here's why. Let me read it. This is the Emergency Use Authorization of medical products, uh, published by the Food and Drug Administration. For FDA to issue an emergency authorization, there must be no adequate approved and available alternative to the candidate product for diagnosing, preventing, or treating the disease or condition. Again, I kept going, why aren't we doing early treatment? Why was the NIH guideline, go home, don't do anything, you know, maybe Tylenol? You know, why weren't we spending hundreds of millions of dollars with an Operation Warp Speed on treatment? I'd asked Francis Collins very early on, so what are you doing in in terms of exploring these cheap generic drugs, 'cause I'd held those hearings and you go, "Senator, we're spending hundreds of millions of dollars." Well, prove it. Send me the documentation. Of course I got no documentation. Yeah, I told a story last night. I was working very early on with the CEO of Novartis, the maker of hydroxychloroquine.

Ron Johnson · 2:16:21

My concern, this was in March, after a state senator from Michigan went public and said, "Boy, I used hydroxychloroquine and I got cured of COVID." Wow, is there a treatment? So I was very excited about that, so was President Trump. Of course, that's what killed hydroxychloroquine, President Trump suggested it. But anyway, so I'm concerned at this point in time, if this is an effective treatment, can we produce enough? So I'm on the phone with the CEO of Novartis and he was all excited about it. He said, "Yeah, we got a bunch of trials, we're gonna be unveiling these things." you know, mid-May, and hopefully they have great, great results. And yeah, we've got the manufacturing capability. They'd already donated 30 million tablets to our national stockpile, but we weren't distributing them. What was interesting about my connection with the, the CEO from Novartis, about the end of April, he went radio silent. I've never heard from him since. So he's all excited. But so something happened, you know, they, the powers to be CDC apparently decided there's not going to be early treatment here.

Ron Johnson · 2:17:24

We've got operational work speed. We're going to use this mRNA platform. We're going to call it something else.